Paclitaxel

Generic Name: Paclitaxel

Brand Names: Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₅₁NO_₁₄

CAS Number: 33069-62-4

Unique Ingredient Identifier: P88XT4IS4D

Background: Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication: Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions: Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer

Associated Therapies: -

Clinical Trials

EndoTAG-1 in Triple Receptor Negative Breast Cancer Patients

Phase 2

Completed

Conditions: Breast Neoplasms

Interventions: Drug: EndoTAG-1 + paclitaxel
Drug: EndoTAG-1
Drug: Paclitaxel

First Posted Date: 2007-03-16

Last Posted Date: 2012-01-05

Lead Sponsor: MediGene

Target Recruit Count: 143

Registration Number: NCT00448305

Locations: 🇧🇪
UZ Antwerpen, Edegem, Belgium
🇧🇪
Institut Jules Bordet - Centre des Tumeurs de l'Université Libre de Bruxelles, Brussels, Belgium
🇧🇪
CHU Brugmann, Brussels, Belgium

and more 30 locations

A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer

Phase 1

Completed

Conditions: Advanced Breast Cancer
Advanced Malignant Solid Tumors
Breast Neoplasms

Interventions: Drug: HKI-272
Drug: Paclitaxel

First Posted Date: 2007-03-09

Last Posted Date: 2018-07-26

Lead Sponsor: Puma Biotechnology, Inc.

Target Recruit Count: 110

Registration Number: NCT00445458

Locations: 🇺🇸
Boston University Medical Center, Boston, Massachusetts, United States
🇺🇸
Mid-Michigan Physicians-HOS Division, Lansing, Michigan, United States
🇨🇦
Princess Margaret Hospital University Health Network, Toronto, Ontario, Canada

and more 29 locations

Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery

Phase 2

Completed

Conditions: Cardiac Toxicity
Breast Cancer

First Posted Date: 2007-02-19

Last Posted Date: 2022-08-05

Lead Sponsor: Mayo Clinic

Target Recruit Count: 122

Registration Number: NCT00436566

Locations: 🇺🇸
Mayo Clinic Cancer Research Consortium, Rochester, Minnesota, United States

A Study of Bevacizumab With Carboplatin and Paclitaxel Chemotherapy for the First-Line Treatment of Patients With Metastatic Melanoma

Phase 2

Completed

Conditions: Melanoma

Interventions: Drug: carboplatin
Drug: bevacizumab
Drug: paclitaxel
Drug: placebo

First Posted Date: 2007-02-13

Last Posted Date: 2017-07-18

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 214

Registration Number: NCT00434252

A Study of Sunitinib in Combination With Bevacizumab, Carboplatin, and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer (SABRE-L)

Phase 2

Terminated

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: bevacizumab
Drug: sunitinib
Drug: paclitaxel
Drug: carboplatin

First Posted Date: 2007-02-13

Last Posted Date: 2009-08-21

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 56

Registration Number: NCT00434226

A Study of Sunitinib in Combination With Bevacizumab and Paclitaxel in Previously Untreated Patients With Metastatic Breast Cancer (SABRE-B)

Phase 2

Terminated

Conditions: Metastatic Breast Cancer

Interventions: Drug: bevacizumab
Drug: sunitinib
Drug: paclitaxel

First Posted Date: 2007-02-13

Last Posted Date: 2009-12-03

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 46

Registration Number: NCT00434356

Combination Chemotherapy With or Without Fluorouracil and/or Pegfilgrastim in Treating Women With Node-Positive Breast Cancer

Phase 3

Active, not recruiting

Conditions: Breast Cancer

First Posted Date: 2007-02-12

Last Posted Date: 2024-05-08

Lead Sponsor: IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy

Target Recruit Count: 2000

Registration Number: NCT00433420

Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer

Phase 3

Active, not recruiting

Conditions: Breast Adenocarcinoma

Interventions: Drug: Cyclophosphamide
Biological: Bevacizumab
Drug: Doxorubicin Hydrochloride
Other: Laboratory Biomarker Analysis
Drug: Paclitaxel
Other: Placebo Administration
Other: Quality-of-Life Assessment

First Posted Date: 2007-02-12

Last Posted Date: 2024-12-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 4994

Registration Number: NCT00433511

Locations: 🇺🇸
Boulder Community Hospital, Boulder, Colorado, United States
🇺🇸
Penrose-Saint Francis Healthcare, Colorado Springs, Colorado, United States
🇺🇸
UCHealth Memorial Hospital Central, Colorado Springs, Colorado, United States

and more 836 locations

Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors

Phase 2

Completed

Conditions: Childhood Germ Cell Tumor
Ovarian Cancer
Teratoma

Interventions: Drug: carboplatin
Drug: etoposide
Drug: ifosfamide
Drug: paclitaxel
Drug: thiotepa
Procedure: autologous hematopoietic stem cell transplantation
Drug: Mesna
Biological: filgrastim

First Posted Date: 2007-02-07

Last Posted Date: 2022-05-17

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 23

Registration Number: NCT00432094

Locations: 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States

Randomized Phase III Trial Comparing Sequential Administration of FE75C Followed by Docetaxel Versus Paclitaxel as Adjuvant Chemotherapy in Axillary Lymph Node (+) Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: Docetaxel
Drug: Paclitaxel
Drug: Epirubicin
Drug: Cyclophosphamide
Drug: 5-fluoruracil
Drug: Granulocyte-colony stimulating growth factor

First Posted Date: 2007-02-05

Last Posted Date: 2008-01-21

Lead Sponsor: Hellenic Oncology Research Group

Target Recruit Count: 478

Registration Number: NCT00431080

Locations: 🇬🇷
"Metaxa's" Anticancer Hospital of Piraeus, 1st Dep of Medical Oncology, Piraeus, Greece
🇬🇷
University General Hospital of Alexandroupolis, Dep of Medical Oncology, Alexandroupolis, Greece
🇬🇷
"Laikon" General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine, Athens, Greece

and more 7 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy